Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.81
LXRX's Cash to Debt is ranked higher than
63% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. LXRX: 2.81 )
LXRX' s 10-Year Cash to Debt Range
Min: 1.31   Max: No Debt
Current: 2.81

Equity to Asset 0.42
LXRX's Equity to Asset is ranked higher than
60% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. LXRX: 0.42 )
LXRX' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.96
Current: 0.42

0.33
0.96
F-Score: 3
Z-Score: -6.03
M-Score: -2.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4094.00
LXRX's Operating margin (%) is ranked higher than
54% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. LXRX: -4094.00 )
LXRX' s 10-Year Operating margin (%) Range
Min: -9955.46   Max: -47.73
Current: -4094

-9955.46
-47.73
Net-margin (%) -4125.63
LXRX's Net-margin (%) is ranked higher than
53% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. LXRX: -4125.63 )
LXRX' s 10-Year Net-margin (%) Range
Min: -10120.39   Max: -47.98
Current: -4125.63

-10120.39
-47.98
ROE (%) -83.03
LXRX's ROE (%) is ranked higher than
61% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. LXRX: -83.03 )
LXRX' s 10-Year ROE (%) Range
Min: -63.41   Max: -16.51
Current: -83.03

-63.41
-16.51
ROA (%) -46.70
LXRX's ROA (%) is ranked higher than
66% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. LXRX: -46.70 )
LXRX' s 10-Year ROA (%) Range
Min: -32.59   Max: -15.27
Current: -46.7

-32.59
-15.27
ROC (Joel Greenblatt) (%) -334.75
LXRX's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. LXRX: -334.75 )
LXRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -490.12   Max: -42.53
Current: -334.75

-490.12
-42.53
Revenue Growth (3Y)(%) -100.00
LXRX's Revenue Growth (3Y)(%) is ranked higher than
52% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. LXRX: -100.00 )
LXRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 52.2
Current: -100

-100
52.2
EBITDA Growth (3Y)(%) -15.10
LXRX's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. LXRX: -15.10 )
LXRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.7   Max: 22.6
Current: -15.1

-28.7
22.6
EPS Growth (3Y)(%) -16.20
LXRX's EPS Growth (3Y)(%) is ranked higher than
71% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. LXRX: -16.20 )
LXRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.1   Max: 30.8
Current: -16.2

-26.1
30.8
» LXRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

LXRX Guru Trades in Q1 2014

Chuck Royce 4,233,933 sh (unchged)
Mario Gabelli 143,200 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Paul Tudor Jones 24,640 sh (-21.45%)
» More
Q2 2014

LXRX Guru Trades in Q2 2014

Mario Gabelli 160,200 sh (+11.87%)
Paul Tudor Jones 24,640 sh (unchged)
Chuck Royce 2,886,133 sh (-31.83%)
» More
Q3 2014

LXRX Guru Trades in Q3 2014

Paul Tudor Jones 29,223 sh (+18.6%)
Mario Gabelli 160,200 sh (unchged)
Chuck Royce 2,736,133 sh (-5.2%)
» More
Q4 2014

LXRX Guru Trades in Q4 2014

Jim Simons 695,910 sh (New)
Paul Tudor Jones 53,297 sh (+82.38%)
Chuck Royce 2,813,833 sh (+2.84%)
Mario Gabelli 105,200 sh (-34.33%)
» More
» Details

Insider Trades

Latest Guru Trades with LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-12-31 Reduce -34.33%$0.85 - $1.48 $ 1.05-9%105200
Mario Gabelli 2012-12-31 Add 509.52%$1.6 - $2.69 $ 1.05-47%128000
Mario Gabelli 2012-09-30 New Buy$2.12 - $3.18 $ 1.05-57%21000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.90
LXRX's P/B is ranked higher than
73% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. LXRX: 6.90 )
LXRX' s 10-Year P/B Range
Min: 0.66   Max: 6.9
Current: 6.9

0.66
6.9
P/S 194.10
LXRX's P/S is ranked lower than
52% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. LXRX: 194.10 )
LXRX' s 10-Year P/S Range
Min: 2.64   Max: 293
Current: 194.1

2.64
293
EV-to-EBIT -5.71
LXRX's EV-to-EBIT is ranked higher than
81% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LXRX: -5.71 )
LXRX' s 10-Year EV-to-EBIT Range
Min: -9.3   Max: -0.1
Current: -5.71

-9.3
-0.1
Current Ratio 1.98
LXRX's Current Ratio is ranked higher than
61% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. LXRX: 1.98 )
LXRX' s 10-Year Current Ratio Range
Min: 0.95   Max: 31.11
Current: 1.98

0.95
31.11
Quick Ratio 1.98
LXRX's Quick Ratio is ranked higher than
63% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. LXRX: 1.98 )
LXRX' s 10-Year Quick Ratio Range
Min: 0.95   Max: 31.11
Current: 1.98

0.95
31.11
Days Sales Outstanding 21.65
LXRX's Days Sales Outstanding is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. LXRX: 21.65 )
LXRX' s 10-Year Days Sales Outstanding Range
Min: 5.95   Max: 461.86
Current: 21.65

5.95
461.86

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -16.40
LXRX's Earnings Yield (Greenblatt) is ranked higher than
59% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. LXRX: -16.40 )
LXRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -18.3   Max: 0
Current: -16.4

-18.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LX3.Germany,
Lexicon Pharmaceuticals Inc was incorporated in Delaware on July 7, 1995. The Company operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. It has used its proprietary gene knockout technology and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. The Company has also advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research and believe that its systematic, target biology-driven approach to drug discovery will enable it to continue to expand its clinical pipeline. It faces significant competition in each of the aspects of its business from other pharmaceutical and biotechnology companies. The development, manufacture and sale of any drug or biologic products developed by the Company or its collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.
» More Articles for LXRX

Headlines

Articles On GuruFocus.com
Lexicon Genetics Inc. Reports Operating Results (10-Q) Nov 08 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) May 10 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Oct 30 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Apr 30 2009 

More From Other Websites
Lexicon tops Street 4Q forecasts Mar 04 2015
Lexicon tops Street 4Q forecasts Mar 04 2015
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2014 Fourth Quarter and Full... Mar 04 2015
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2014 Fourth Quarter And Full... Mar 04 2015
4 Stocks Under $10 Triggering Breakout Trades Mar 03 2015
Lexicon Announces Management Change Mar 03 2015
Lexicon to Report Fourth Quarter and Year End 2014 Financial Results on March 4, 2015 Mar 02 2015
Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 Mar 02 2015
Lexicon To Present At The Cowen 35th Annual Health Care Conference Feb 26 2015
Lexicon Announces Management Change Feb 23 2015
Lexicon to Present at the Bio Ceo & Investor Conference Feb 06 2015
Lexicon To Present At The BIO CEO & Investor Conference Feb 06 2015
LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Feb 05 2015
Lexicon to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
Lexicon To Present At The 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 23 2014
Lexicon Pharmaceuticals (LXRX): Strong Industry, Solid Earnings Estimate Revisions Dec 15 2014
LEXICON PHARMACEUTICALS, INC. Financials Dec 11 2014
Lexicon to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 08 2014
Lexicon To Present At The Oppenheimer 25th Annual Healthcare Conference Dec 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK